BRKR vs DHR vs RGEN Stock Comparison

Bruker, Danaher and Repligen Prices as of Nov 13, 2026 Peers: Industry group
BRKR Bruker Corp
$61.59 +10.8% 1M +47.4% 1Y
Market cap
$9.35B
P/E
–
Revenue (TTM)
$3.51B
Div. yield
0.00%
Life Sciences Tools Healthcare
1 win
DHR Danaher Corp /De/
$233.03 +3.7% 1M +5.3% 1Y
Market cap
$162.96B
P/E
37.6x
Revenue (TTM)
$25.61B
Div. yield
–
Life Sciences Tools Healthcare
7 wins
RGEN Repligen Corp
$167.79 -5.8% 1M +11.4% 1Y
Market cap
$9.30B
P/E
–
Revenue (TTM)
$805.61M
Div. yield
–
Life Sciences Tools Healthcare
2 wins

Head to Head

10 decided of 12

Danaher leads on 7 of the 12 questions below (Danaher 7, Repligen 2, Bruker 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionBRKRDHRRGENLeader
Larger companyMarket capitalisation $9.35B $162.96B $9.30B DHR
Cheaper on earningsLower P/E, profitable companies only -55.9x 37.6x -788.3x –
Cheaper on forward earningsLower price / next fiscal year consensus EPS 28.0x 25.6x 86.0x DHR
Faster revenue growthRevenue growth, trailing twelve months +2.2% +5.5% +13.8% RGEN
More profitableNet margin, trailing twelve months -4.8% 16.9% -1.5% DHR
Better return on capitalReturn on invested capital -1.7% 5.8% 0.0% DHR
Less leveragedLower net debt / EBITDA 10.0x 2.6x -2.8x RGEN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +47.4% +5.3% +11.4% BRKR
Better 5-year returnAnnualised price return, 5 years -5.7%/yr -5.2%/yr -8.3%/yr DHR
Less volatileAnnualised volatility, 1 year 62.4% 31.0% 46.5% DHR
Higher overall scoreMean of the five percentile scores vs peers 48/100 60/100 58/100 DHR

Percentile Scorecard

BRKRDHRRGEN

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisBRKRDHRRGEN
Valuation 69 #77 of 243 69 #76 of 243 56 #108 of 243
Growth 18 #187 of 228 25 #172 of 228 30 #161 of 228
Profitability 63 #82 of 222 86 #32 of 222 67 #75 of 222
Financial Health 19 #200 of 248 47 #133 of 248 80 #50 of 248
Shareholder Returns 69 #50 of 158 73 #44 of 158 57 #68 of 158
Overall 48 60 58
  • BRKR ranked among 252 companies in Medical Devices and Diagnostics
  • DHR ranked among 252 companies in Medical Devices and Diagnostics
  • RGEN ranked among 252 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodBRKRDHRRGENSPY
1 month +10.8%+3.7%-5.8% -2.0%
3 months +6.7%+15.1%+0.6% -2.8%
6 months +43.6%+43.9%+63.1% +2.0%
Year to date +30.7%+1.8%+2.4% +10.6%
1 year +47.4%+5.3%+11.4% +12.2%
3 years -0.1%+14.5%+9.1% +68.1%
3 years, per year 0.0%+4.6%+2.9% +18.9%
5 years -25.4%-23.4%-35.1% +61.4%
5 years, per year -5.7%-5.2%-8.3% +10.1%
10 years +169.3%+187.9%+419.6% +248.5%
10 years, per year +10.4%+11.2%+17.9% +13.3%

Risk

MeasureBRKRDHRRGENSPY
Volatility, 1Y 62.4%31.0%46.5% 13.6%
Downside volatility, 1Y 59.9%32.4%47.4% 13.9%
Beta vs S&P 500, 1Y 1.750.551.21 1.00
Return / volatility, 1Y 0.760.170.25 0.90
Max drawdown, 5Y -68.9%-50.8%-64.7% -25.4%
From 52-week high -7.4%-3.7%-13.8% -3.2%
52-week high $66.54$242.05$194.57 $779.14
52-week low $32.76$161.91$102.87 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleBRKRDHRRGEN
P/E now vs peer median -56.1xmedian 26.5x 37.9xmedian 26.5x -804.0xmedian 26.5x
P/S now vs peer median 2.7xmedian 2.7x 6.4xmedian 2.7x 11.8xmedian 2.7x
EV/EBITDA now vs peer median 69.3xmedian 18.4x 23.5xmedian 18.4x 83.9xmedian 18.4x
P/FCF now vs peer median 38.4xmedian 25.4x 28.6xmedian 25.4x 89.1xmedian 25.4x
P/B now vs peer median 4.1xmedian 2.5x 3.1xmedian 2.5x 4.5xmedian 2.5x
PEG now vs peer median 1.57median 0.98 -4.72median 0.98 28.28median 0.98

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsBRKRDHRRGEN
Revenue $3.51B $25.61B $805.61M
Gross profit $1.67B $15.01B $430.67M
Operating income -$69.80M $5.22B $18.24M
Net income -$115.70M $4.33B -$11.80M
Free cash flow $244.70M $5.73B $106.72M
R&D $387.20M $1.67B $57.23M
EPS (diluted) $-1.10 $6.13 $-0.21
Cash & equivalents $119.70M $5.68B $726.96M
Total debt $1.71B $26.48B $555.60M
Shares (diluted) 152.50M 706.80M 56.56M
Enterprise value $8.62B $142.61B $6.08B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricBRKRDHRRGEN
P/E -56.1x 37.9x -804.0x
P/FCF 38.4x 28.6x 89.1x
P/Operating cash flow 27.5x 23.9x 73.2x
P/S 2.7x 6.4x 11.8x
P/B 4.1x 3.1x 4.5x
P/Tangible book 4.2x 5.0x 5.3x
EV/EBITDA 69.3x 23.5x 83.9x
EV/EBIT -157.6x 35.4x 504.7x
EV/Revenue 3.1x 7.2x 11.4x
EV/FCF 45.0x 32.3x 86.3x
EV/Operating cash flow 32.2x 26.9x 70.9x
PEG (3Y EPS CAGR) 1.57 -4.72 28.28

Growth

14 metrics
MetricBRKRDHRRGEN
Revenue growth (1Y) 2.2% 5.5% 13.8%
Revenue CAGR (3Y) 7.6% 1.3% 7.3%
Gross profit growth (1Y) 3.2% 3.9% 33.0%
Gross profit CAGR (3Y) 4.9% 1.2% 13.3%
Operating income growth (1Y) -209.1% 13.1% 2,185%
Operating income CAGR (3Y) -29.1% -3.8% -40.5%
Net income growth (1Y) -390.3% 23.6% -779.2%
Net income CAGR (3Y) -33.1% -9.9% -28.4%
EPS growth (1Y) -602.7% 24.8% -778.9%
EPS CAGR (3Y) -35.8% -8.0% -28.4%
Operating cash flow growth (1Y) 262.5% 8.6% -0.8%
Operating cash flow CAGR (3Y) 2.6% -5.3% 5.3%
Free cash flow growth (1Y) 2,408% 14.2% -3.0%
Free cash flow CAGR (3Y) 5.9% -5.8% 17.6%

Profitability

14 metrics
MetricBRKRDHRRGEN
Gross margin 47.7% 58.6% 53.5%
EBITDA margin 4.5% 30.7% 13.6%
Operating margin -2.0% 20.4% 2.3%
Pretax margin -2.0% 18.8% 1.0%
Net margin -4.8% 16.9% -1.5%
FCF margin 7.0% 22.4% 13.2%
Operating cash flow margin 9.7% 26.8% 16.1%
Return on equity -4.9% 8.2% -1.7%
Return on assets -2.0% 4.7% -1.2%
Return on invested capital -1.7% 5.8% 0.0%
Return on capital employed -1.5% 6.2% 0.6%
Asset turnover 0.6x 0.3x 0.3x
Cash conversion (OCF / net income) -3.0x 1.6x -11.0x
Stock comp / revenue – 1.3% 4.2%

Financial Health

11 metrics
MetricBRKRDHRRGEN
Debt / assets 29.4% 28.4% 19.0%
Debt / equity 0.7x 0.5x 0.3x
Net debt / EBITDA 10.0x 2.6x -2.8x
Debt / FCF 7.0x 4.6x 5.2x
Liabilities / assets 60.4% 42.5% 28.5%
Equity / assets 39.6% 57.5% 71.5%
Interest coverage -1.2x 14.5x 0.8x
Current ratio 1.8x 1.6x 9.9x
Quick ratio 0.7x 1.1x 8.1x
Cash ratio 0.1x 0.6x 6.9x
Altman Z-score – 3.75 7.80

Shareholder Returns

7 metrics
MetricBRKRDHRRGEN
Dividend yield 0.3% 0.7% –
Net buyback yield – 0.5% -0.2%
Shareholder yield 0.3% 1.1% -0.2%
Payout ratio (earnings) -26.2% – –
Payout ratio (FCF) 12.4% – –
Dividend growth (1Y) 32.3% – –
Dividend CAGR (3Y) 0.9% – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusBRKRDHRRGEN
Forward P/E 28.0xFY2026 25.6xFY2026 86.0xFY2026
EPS, next fiscal year $2.20FY2026 $9.12FY2026 $1.95FY2026
EPS growth, next FY +20.2%FY2026 +16.9%FY2026 +14.0%FY2026
EPS growth, the year after +5.5% +7.9% +29.2%
Revenue, next fiscal year $3.76BFY2026 $27.01BFY2026 $791.31MFY2026
Revenue growth, next FY +9.4%FY2026 +9.9%FY2026 +7.2%FY2026
Revenue growth, the year after +2.7% -1.9% +44.3%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersBRKRDHRRGEN
Held by institutions 93.1% 81.9% 100.0%
Institutions holding 418 2,121 483
Change in shares held, QoQ +3.6% +1.1% +1.2%
Institutions buying 249 841 273
Institutions selling 122 1,016 141
Buyers to sellers 2.04 0.83 1.94

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

BRKRDHRRGEN
BRKR 1.00 0.43 0.52
DHR 0.43 1.00 0.64
RGEN 0.52 0.64 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, BRKR, DHR and RGEN?

Danaher (DHR) is the largest by market capitalisation: Bruker (BRKR) $9.35B, Danaher (DHR) $162.96B, Repligen (RGEN) $9.30B.

Which company is growing faster?

Repligen (RGEN) grew revenue fastest over the trailing twelve months: Bruker (BRKR) +2.2%, Danaher (DHR) +5.5%, Repligen (RGEN) +13.8%.

Which company is more profitable?

Danaher (DHR) has the highest net margin (Bruker (BRKR) -4.8%, Danaher (DHR) 16.9%, Repligen (RGEN) -1.5%). On return on invested capital, Danaher (DHR) leads (Bruker (BRKR) -1.7%, Danaher (DHR) 5.8%, Repligen (RGEN) 0.0%).

Which stock has performed better?

Over the past year Bruker (BRKR) returned the most: Bruker (BRKR) +47.4%, Danaher (DHR) +5.3%, Repligen (RGEN) +11.4%. Over five years, Danaher (DHR) compounded fastest (Bruker (BRKR) -5.7%/yr, Danaher (DHR) -5.2%/yr, Repligen (RGEN) -8.3%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Only one of these companies pays a dividend: Bruker (BRKR) 0.00%, Danaher (DHR) 0.00%, Repligen (RGEN) 0.00%. Danaher (DHR) and Repligen (RGEN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Danaher (DHR) has been the steadiest (Bruker (BRKR) 62.4%, Danaher (DHR) 31.0%, Repligen (RGEN) 46.5%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, BRKR, DHR and RGEN?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Danaher (DHR) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.